Naschitz Brandes Amir offers a depth of experience serving the needs of innovative biotechnology companies ranging from startups to multinational corporations and everything in between, as well as venture capital firms, investors, and investment institutions within the life sciences ecosystem that support those companies.
Primary areas where we assist our BioTech clients include venture financing, M&A and technology transactions, strategic collaborations, licensing, intellectual property, litigation and dispute resolution, labor and employment, real estate, and environmental.
How we help our clients:
- Venture Formation
- Corporate transactions, including mergers and acquisitions
- Commercial finance and restructurings
- Corporate governance
- Supply/distribution agreements
- Franchising
- International trade
- Environmental and permitting
- Patent prosecution
- Licensing
- Real Estate
- Trademarks
- Tax
- Technology transactions
- Research agreements and secondary use of data
MeMed Diagnostics
Advised MeMed, a med tech and bio-convergence company, on a number of its financing rounds. We have represented MeMed Diagnostics on a range of matters since its incorporation, including the signing of a strategic partnership with Italian Biotech giant DiaSorin to market and develop the company’s products.
Macrocure
Represented controlling shareholders in the $55 million NASDAQ IPO of MacroCure, a company focused on the development of advanced cell therapy products.
Seer
Advised the shareholders on the $2.5 billion IPO of Seer, a biotechnology company in the field of proteomics.
Opus Chartered Issuances SA
Advised Opus Chartered in its Series B investment in Pepticom, a drug discovery startup.
aMoon
Advised aMoon Fund on a number of matters including its investments in biotech and life sciences startups, including Aummune, MDClone and Vocalis, and in its role as lead investor on a $55 million Series D equity financing in Seer.
Curesponse
Advised Curesponse, a clinical-stage cancer diagnostics startup, in its Series A investment.
Spatz FGIA
Served as a trial counsel for Spatz FGIA, a developer of non-surgical medical solutions for the treatment of obesity, in a disciplinary procedure held by the Israeli Ministry of Health.
Cardiovascular Systems
Represented US-based Cardiovascular Systems (NASDAQ: CSII) in its acquisition of the WIRION Embolic Protection System and related assets from Allium Medical (TASE: ALMD) and it's subsidiary Gardia Medical.
Ferring Holding and Bio-Technology General Israel
Representing Ferring Holding and Bio-Technology General Israel, subsidiaries of Ferring in their legal and regulatory affairs in Israel including collaborations with hospitals and scientific institutions involved in drug discovery research.
Pepticom
Advising Pepticom, a peptide drug discovery company, on numerous regulatory and commercial matters including collaboration agreements with scientific institutions, research centers, and leading pharmaceutical companies.
FIMI Opportunity Funds
Represented FIMI, a leading Israeli private equity firm in a $25 million private placement transaction with Kamada (NASDAQ, TASE: KMDA), a plasma-derived protein therapeutics company.
Israel Biotech Fund
Advised Israel Biotech Fund in a $15 million Round C investment in BioSight, a pharmaceutical development company.